A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.

Also called NCT05901831

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 242 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05901831
  • EU CT 2022-503024-27-00
Other papers using this trial's data
  • Finerenone in Type 1 Diabetes and Chronic Kidney Disease The New England journal of medicine, 2026-03-05 DOI, PubMed 41780000

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, China, Denmark, Germany, Italy, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05901831. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-26 (actual); primary completion 2025-08-20 (actual). Results posted on 2026-10-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Acronym
FINE-ONE
Condition
Type 1 Diabetes Mellitus
Intervention (Drug)
Finerenone
Intervention (Other)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct05901831
Content hash
d7fd286f4411d74fba1490ec13002569a63a21c98f7a054d67a9db29cda04588